Literature DB >> 21399589

Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran.

D Ahmad1, S Mehdi, H H Sayed, A K Sayed, G Shirzad.   

Abstract

Schizophrenia is a severe neuropsychiatric disorder of unknown etiology. As there is little information about the association between Toxoplasma gondii infection and schizophrenia in Iran, we investigated the seroprevalence of T. gondii in these patients and compared with that obtained in control individuals in Sari City, Iran, 2009. Eighty schizophrenia patients and 99 healthy people were examined for the presence of IgG and IgM antibodies to T. gondii by enzyme linked immunosorbent assay (ELISA). Overall prevalence rates of anti-T. gondii antibodies (IgG/IgM) in case and control groups were 72.5% and 61.6%, respectively (P>0.05). IgG antibodies indicating chronic form of toxoplasmosis were found in 28 (35%) and 25 (25.3%) of case and control groups, respectively (P>0.05). IgM antibodies (acute form) were also seen in 9 (11.2%) and 11 (11.1%) of case and control individuals, respectively (P>0.05). The highest 10th percentile of IgG titers in schizophrenia individuals (18.8%) was significantly higher than control group (6.1%, P=0.02). As prevalence rate of T. gondii antibodies in patients with schizophrenia was high, it seems that designing a cohort study will determine the causative relationship between Toxoplasma infection and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21399589

Source DB:  PubMed          Journal:  Trop Biomed        ISSN: 0127-5720            Impact factor:   0.623


  16 in total

1.  Toxoplasma gondii and other risk factors for schizophrenia: an update.

Authors:  E Fuller Torrey; John J Bartko; Robert H Yolken
Journal:  Schizophr Bull       Date:  2012-03-23       Impact factor: 9.306

2.  Serological and molecular diagnosis of Toxoplasma gondii in patients with schizophrenia.

Authors:  Adel Ebrahimzadeh; Mehdi Khoshsima Shahraki; Azad Mohammadi
Journal:  J Parasit Dis       Date:  2018-03-08

3.  Pathobiology of human RH strain induced experimental toxoplasmosis in murine model.

Authors:  Vikrant Sudan; A K Tewari; Harkirat Singh; R Singh
Journal:  J Parasit Dis       Date:  2014-10-01

4.  Seroprevalence of Toxoplasma Gondii Infection among High School Girls in Ajabshir from East Azarbaijan Province, Iran.

Authors:  Esmaeil Fallah; Arash Rasuli; Abbas Shahbazi; Morteza Ghojazadeh; Majid Khanmohammadi; Fatemeh Hamzavi; Roghayeh Roshanaei
Journal:  J Caring Sci       Date:  2014-09-01

5.  Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis.

Authors:  Joel M Monroe; Peter F Buckley; Brian J Miller
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

Review 6.  Toxoplasmosis and neuropsychiatric diseases: can serological studies establish a clear relationship?

Authors:  Silvia Fabiani; Barbara Pinto; Fabrizio Bruschi
Journal:  Neurol Sci       Date:  2012-09-26       Impact factor: 3.307

7.  Association between infection with Toxoplasma gondii and psychiatric disorders.

Authors:  Alia Maisarah; Suharni Mohamad; Maruzairi Husain; Sarimah Abdullah; Rahmah Noordin
Journal:  Folia Parasitol (Praha)       Date:  2022-04-04       Impact factor: 2.122

8.  The correlation between Toxoplasma gondii infection and Parkinson's disease: a case-control study.

Authors:  Mahmoud Mahami Oskouei; Faezeh Hamidi; Mahnaz Talebi; Mehdi Farhoudi; Ali Akbar Taheraghdam; Tohid Kazemi; Homayoun Sadeghi-Bazargani; Esmaeil Fallah
Journal:  J Parasit Dis       Date:  2014-10-14

9.  MOLECULAR CHARACTERIZATION AND SEQUENCE PHYLOGENETIC ANALYSIS OF SURFACE ANTIGEN 3 (SAG3) GENE OF LOCAL INDIAN ISOLATES (CHENNAI AND IZATNAGAR) OF Toxoplasma gondii.

Authors:  Vikrant Sudan; Anup Kumar Tewari; Harkirat Singh
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 May-Jun       Impact factor: 1.846

10.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.